DOCSLIB.ORG

Implication of the Anti-Inflammatory Bioactive Lipid Prostaglandin D2-Glycerol Ester in the Control of Macrophage Activation

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Implication of the Anti-Inflammatory Bioactive Lipid Prostaglandin D2-Glycerol Ester in the Control of Macrophage Activation Implication of the anti-inflammatory bioactive lipid prostaglandin D2-glycerol ester in the control of macrophage activation and inflammation by ABHD6 Mireille Alhouayeka,b,1, Julien Masqueliera,1, Patrice D. Canic, Didier M. Lambertb, and Giulio G. Mucciolia,2 aBioanalysis and Pharmacology of Bioactive Lipids Research Group, Louvain Drug Research Institute, Université catholique de Louvain, B-1200 Brussels, Belgium; bMedicinal Chemistry Research Group, Louvain Drug Research Institute, Université catholique de Louvain, B-1200 Brussels, Belgium; and cMetabolism and Nutrition Research Group, Walloon Excellence in Life sciences and BIOtechnology (WELBIO), Louvain Drug Research Institute, Université catholique de Louvain, B-1200 Brussels, Belgium Edited by Charles N. Serhan, Brigham and Women’s Hospital /Harvard Medical School, Boston, MA, and accepted by the Editorial Board September 5, 2013 (received for review July 24, 2013) Proinflammatory macrophages are key mediators in several pathol- MAGL controls around 80% of 2-AG hydrolysis, it remains ogies; thus, controlling their activation is necessary. The endocanna- unclear whether this occurs in other tissues (13, 14). Because of binoid system is implicated in various inflammatory processes. Here this control of brain 2-AG levels, inhibition of MAGL leads to we show that in macrophages, the newly characterized enzyme increased central levels of 2-AG and therefore to undesirable α β / -hydrolase domain 6 (ABHD6) controls 2-arachidonoylglycerol psychotropic side effects due to activation of the CB1 cannabinoid (2-AG) levels and thus its pharmacological effects. Furthermore, receptor (15). More recently, other enzymes have been impli- we characterize a unique pathway mediating the effects of 2-AG cated in 2-AG hydrolysis, such as the newly annotated enzyme through its oxygenation by cyclooxygenase-2 to give rise to the α/β-hydrolase domain 6 (ABHD6) (16–19). Here, we demonstrate fl anti-in ammatory prostaglandin D2-glycerol ester (PGD2-G). Pharma- the anti-inflammatory effects of inhibiting ABHD6 and thus in- cological blockade of cyclooxygenase-2 or of prostaglandin D syn- creasing 2-AG levels, without the side effects of MAGL inhibition. thase prevented the effects of increasing 2-AG levels by ABHD6 Classically, 2-AG binds to and activates two G-protein–coupled – inhibition in vitro, as well as the 2-AG induced increase in PGD2-G receptors, termed cannabinoid receptors 1 and 2 (CB1 and CB2); levels. Together, our data demonstrate the physiological relevance however, it may also activate the peroxisome proliferator-activated of the interaction between the endocannabinoid and prostanoid receptors (PPARs) (20). Alternatively, this endogenous lipid, like systems. Moreover, we show that ABHD6 inhibition in vivo allows arachidonic acid, may also be oxidized by cyclooxygenase (COX) for fine-tuning of 2-AG levels in mice, therefore reducing lipopoly- enzymes to produce prostaglandin glycerol esters (PG-Gs) (21). saccharide-induced inflammation, without the characteristic central So far, the biological effects of these PG-Gs are not fully eluci- side effects of strong increases in 2-AG levels obtained following dated. In this study, we also demonstrate that following increased monoacylglycerol lipase inhibition. In addition, administration of 2-AG levels in macrophages, COX-2–mediated production of fl PGD2-G reduces lipopolysaccharide-induced in ammation in mice, PGD -G increases, resulting in the anti-inflammatory effects ob- fi 2 thus con rming the biological relevance of this 2-AG metabolite. This served with 2-AG (Fig. S1). We also put forth, in vivo, the anti- points to ABHD6 as an interesting therapeutic target that should be inflammatory properties of PGD2-G. relevant in treating inflammation-related conditions, and proposes PGD -G as a bioactive lipid with potential anti-inflammatory proper- 2 Significance ties in vivo. COX-2 | prostaglandin synthase | glyceryl prostaglandin | FAAH | 2-Arachidonoylglycerol (2-AG) is an endogenous bioactive lipid anandamide implicated in numerous (patho)physiological processes. 2-AG classically activates the cannabinoid receptors, and its activity is terminated by enzymatic hydrolysis. The main enzyme studied acrophages are key players in innate and adaptive immune in this context is monoacylglycerol lipase (MAGL). Although its Mresponses to bacterial infections or noxious agents. Their inhibition, to increase 2-AG levels, has proven beneficial, it is role during inflammatory processes is to eliminate the threat and fl hindered by psychotropic side effects due to drastically elevated protect the body (1, 2). Macrophages exhibiting an in ammatory brain 2-AG. Here we show the anti-inflammatory effects of in- fl phenotype secrete proin ammatory mediators and reactive ox- hibition of another 2-AG hydrolase, α/β-hydrolase domain 6, fl ygen and nitrogen species that in uence the polarization of T- without the side effects associated with MAGL inhibition. We helper cells, further drive the inflammatory response, and acti- also show that 2-AG decreases macrophage activation and this vate various antimicrobial mechanisms (3). Under persistence of effect is not mediated by its classical receptors. Furthermore, the proinflammatory phase, inflammation becomes chronic, thus we demonstrate that a cyclooxygenase-2–derived metabolite of deleterious (3). Macrophages are key mediators in the immu- 2-AG, prostaglandin D2-glycerol ester, is responsible for the nopathology of metabolic inflammation and autoimmune dis- documented effects. eases such as inflammatory bowel disease (IBD) and rheumatoid arthritis (2, 4). Thus, in these pathologies, proinflammatory Author contributions: M.A. and G.G.M. designed research; M.A., J.M., and G.G.M. performed macrophage responses must be controlled and reduced. research; G.G.M. contributed new reagents/analytic tools; D.M.L. and P.D.C. provided re- agents; M.A., J.M., and G.G.M. analyzed data; and M.A., J.M., P.D.C., D.M.L., and G.G.M. The endocannabinoid 2-arachidonoylglycerol (2-AG) is in- wrote the paper. volved in various (patho)physiological processes and exerts nu- The authors declare no conflict of interest. fi merous bene cial actions (ranging from pain modulation to This article is a PNAS Direct Submission. C.N.S. is a guest editor invited by the Editorial reduction of anxiety) (5–11). The activity of this bioactive lipid Board. depends on its endogenous levels, tightly controlled by the 2-AG 1M.A. and J.M. contributed equally to this work. hydrolyzing enzymes (12). Monoacylglycerol lipase (MAGL) is 2To whom correspondence should be addressed. E-mail: [email protected]. thought to be the primary enzyme responsible for 2-AG me- This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10. tabolism. Although this has been proven in the brain, where 1073/pnas.1314017110/-/DCSupplemental. 17558–17563 | PNAS | October 22, 2013 | vol. 110 | no. 43 www.pnas.org/cgi/doi/10.1073/pnas.1314017110 Downloaded by guest on September 24, 2021 Results The results obtained in J774 cells were confirmed further in ABHD6, but Not MAGL, Inhibition Reduces Macrophage Activation. primary peritoneal macrophages, a more physiological model, as Lipopolysaccharide (LPS), a component of the cell wall of Gram- well as in other macrophage-like cell lines, such as RAW264.7 negative bacteria, is a potent macrophage activator (22). Macro- cells and the BV2 microglial cell line. Indeed, treatment of these phages activated with LPS release several proinflammatory cyto- cells with WWL70 significantly increased 2-AG levels (Fig. 1H kines, such as IL-1β, IL-6, and TNF-α, and produce nitric oxide and Fig. S5A), thus leading to a decrease in LPS-induced mac- I J B D (Fig. S2A) and prostaglandins (PGs). rophage activation (Fig. 1 and and Fig. S5 and ), as To assess the implication of ABHD6 in 2-AG metabolism by measured by mRNA expression of IL-1β as well as PG pro- macrophages, J774 macrophages incubated with increasing doses duction. Quantitative PCR (qPCR) for mRNA expression of fi of the selective ABHD6 inhibitor WWL70 (17, 23, 24) were MAGL and ABHD6 con rmed the absence of MAGL in the D–F stimulated with LPS. WWL70 induced a dose-dependent in- RAW264.7 cells, as well as the presence of ABHD6 (Fig. S4 ). crease in 2-AG levels (Fig. 1A), with an EC50 of 0.3 μM. In- creasing exogenous or endogenous 2-AG levels by exposing the The Effect of 2-AG and ABHD6 Inhibition Is Independent of Cannabinoid Receptors or PPARs. 2-AG is an agonist at both the CB and CB cells to increasing concentrations of 2-AG and WWL70 resulted 1 2 cannabinoid receptors (20). To determine whether the effect of 2- in a dose-dependent decrease of IL-1β mRNA expression (Fig. AG on LPS-induced macrophage activation is CB /CB de- 1B), with an IC of the same order of magnitude for the two 1 2 50 pendent, we used selective antagonists of these receptors, namely compounds: 6 μM for 2-AG and 1 μM for WWL70. Additionally, SLV319 (SLV, 1μM) and SR141716A (SR1, 1μM) for CB and 2-AG did not decrease macrophage activation when the cells 1 SR144528 (SR2, 1μM) for CB . Coincubation of these antagonists were assessed at 24 h, whereas WWL70 retained its efficacy (Fig. 2 with either 2-AG or WWL70 in the J774 and RAW264.7 cell lines S3A). This probably is a result of the lower stability of 2-AG in did not block their effect on macrophage activation (Figs. S3D and the medium or its hydrolysis by ABHD6 in the absence of the S5E). To further confirm that the decrease observed following inhibitor, thus strengthening the rationale to use enzyme inhib- ABHD6 inhibition is not cannabinoid receptor dependent, itors to increase this bioactive lipid’s levels and make use of its we used two potent CB1/CB2 agonists, HU210 (100 nM) and therapeutic potential. The effect of WWL70 and 2-AG was CP55,940 (100 nM) (20).
Load more

Recommended publications
  • The Expanded Endocannabinoid System/Endocannabinoidome As a Potential Target for Treating Diabetes Mellitus
    Current Diabetes Reports (2019) 19:117 https://doi.org/10.1007/s11892-019-1248-9 OBESITY (KM GADDE, SECTION EDITOR) The Expanded Endocannabinoid System/Endocannabinoidome as a Potential Target for Treating Diabetes Mellitus Alain Veilleux1,2,3 & Vincenzo Di Marzo1,2,3,4,5 & Cristoforo Silvestri3,4,5 # Springer Science+Business Media, LLC, part of Springer Nature 2019 Abstract Purpose of Review The endocannabinoid (eCB) system, i.e. the receptors that respond to the psychoactive component of cannabis, their endogenous ligands and the ligand metabolic enzymes, is part of a larger family of lipid signals termed the endocannabinoidome (eCBome). We summarize recent discoveries of the roles that the eCBome plays within peripheral tissues in diabetes, and how it is being targeted, in an effort to develop novel therapeutics for the treatment of this increasingly prevalent disease. Recent Findings As with the eCB system, many eCBome members regulate several physiological processes, including energy intake and storage, glucose and lipid metabolism and pancreatic health, which contribute to the development of type 2 diabetes (T2D). Preclinical studies increasingly support the notion that targeting the eCBome may beneficially affect T2D. Summary The eCBome is implicated in T2D at several levels and in a variety of tissues, making this complex lipid signaling system a potential source of many potential therapeutics for the treatments for T2D. Keywords Endocannabinoidome . Bioactive lipids . Peripheral tissues . Glucose . Insulin Introduction: The Endocannabinoid System cannabis-derived natural product, Δ9-tetrahydrocannabinol and its Subsequent Expansion (THC), responsible for most of the psychotropic, euphoric to the “Endocannabinoidome” and appetite-stimulating actions (via CB1 receptors) and immune-modulatory effects (via CB2 receptors) of marijuana, The discovery of two G protein-coupled receptors, the canna- opened the way to the identification of the endocannabinoids binoid receptor type-1 (CB1) and − 2 (CB2) [1, 2], for the (eCBs).
    [Show full text]
  • Harnessing the Endocannabinoid 2-Arachidonoylglycerol to Lower Intraocular Pressure in a Murine Model
    Glaucoma Harnessing the Endocannabinoid 2-Arachidonoylglycerol to Lower Intraocular Pressure in a Murine Model Sally Miller,1 Emma Leishman,1 Sherry Shujung Hu,2 Alhasan Elghouche,1 Laura Daily,1 Natalia Murataeva,1 Heather Bradshaw,1 and Alex Straiker1 1Department of Psychological and Brain Sciences, Indiana University, Bloomington, Indiana, United States 2Department of Psychology, National Cheng Kung University, Tainan, Taiwan Correspondence: Alex Straiker, De- PURPOSE. Cannabinoids, such as D9-THC, act through an endogenous signaling system in the partment of Psychological and Brain vertebrate eye that reduces IOP via CB1 receptors. Endogenous cannabinoid (eCB) ligand, 2- Sciences, Indiana University, Bloom- arachidonoyl glycerol (2-AG), likewise activates CB1 and is metabolized by monoacylglycerol ington, IN 47405, USA; lipase (MAGL). We investigated ocular 2-AG and its regulation by MAGL and the therapeutic [email protected]. potential of harnessing eCBs to lower IOP. Submitted: February 16, 2016 Accepted: May 16, 2016 METHODS. We tested the effect of topical application of 2-AG and MAGL blockers in normotensive mice and examined changes in eCB-related lipid species in the eyes and spinal Citation: Miller S, Leishman E, Hu SS, cord of MAGL knockout (MAGLÀ/À) mice using high performance liquid chromatography/ et al. Harnessing the endocannabinoid tandem mass spectrometry (HPLC/MS/MS). We also examined the protein distribution of 2-arachidonoylglycerol to lower intra- ocular pressure in a murine model. MAGL in the mouse anterior chamber. Invest Ophthalmol Vis Sci. RESULTS. 2-Arachidonoyl glycerol reliably lowered IOP in a CB1- and concentration-dependent 2016;57:3287–3296. DOI:10.1167/ manner. Monoacylglycerol lipase is expressed prominently in nonpigmented ciliary iovs.16-19356 epithelium.
    [Show full text]
  • Control of Analgesic and Anti-Inflammatory Pathways by Fatty Acid Amide Hydrolase Long, James Harry
    Control of analgesic and anti-inflammatory pathways by fatty acid amide hydrolase Long, James Harry The copyright of this thesis rests with the author and no quotation from it or information derived from it may be published without the prior written consent of the author For additional information about this publication click this link. http://qmro.qmul.ac.uk/jspui/handle/123456789/3124 Information about this research object was correct at the time of download; we occasionally make corrections to records, please therefore check the published record when citing. For more information contact [email protected] Control of analgesic and anti-inflammatory pathways by fatty acid amide hydrolase James Harry Long Thesis submitted for the degree of Doctor of Philosophy to the University of London Translational Medicine and Therapeutics William Harvey Research Institute Charterhouse Square, London, EC1M 6BQ Table of contents Table of Contents Declaration VIII Acknowledgements IX Abstract X Abbreviations XI Chapter 1 – Introduction 1 1.1. Pain and analgesia 2 1.1.1. Nociception 2 1.1.2. Inflammatory pain 5 1.1.3. Neuropathic pain 10 1.1.4. Analgesia 10 1.1.5. COX inhibitors 11 1.1.6. Opioid receptor agonists 12 1.1.7. Glucocorticoids 13 1.1.8. Anaesthetics 13 1.1.9. Antidepressants 14 1.1.10. Anticonvulsants 14 1.1.11. Muscle relaxants 15 1.1.12. An alternative analgesic pathway 15 1.2. Endocannabinoid system 16 1.2.1. Cannabinoid receptors 16 1.2.2. Endocannabinoids 18 1.2.3. Endocannabinoid biosynthesis 21 1.2.4. Endocannabinoid metabolism 21 1.2.5.
    [Show full text]
  • Chemical Probes to Potently and Selectively Inhibit Endocannabinoid
    Chemical probes to potently and selectively inhibit PNAS PLUS endocannabinoid cellular reuptake Andrea Chiccaa,1, Simon Nicolussia,1, Ruben Bartholomäusb, Martina Blunderc,d, Alejandro Aparisi Reye, Vanessa Petruccia, Ines del Carmen Reynoso-Morenoa,f, Juan Manuel Viveros-Paredesf, Marianela Dalghi Gensa, Beat Lutze, Helgi B. Schiöthc, Michael Soeberdtg, Christoph Abelsg, Roch-Philippe Charlesa, Karl-Heinz Altmannb, and Jürg Gertscha,2 aInstitute of Biochemistry and Molecular Medicine, National Centre of Competence in Research NCCR TransCure, University of Bern, 3012 Bern, Switzerland; bDepartment of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences, ETH Zurich, 8093 Zurich, Switzerland; cDepartment of Neuroscience, Biomedical Center, Uppsala University, 751 24 Uppsala, Sweden; dBrain Institute, Universidade Federal do Rio Grande do Norte, Natal 59056- 450, Brazil; eInstitute of Physiological Chemistry, University Medical Center of the Johannes Gutenberg University Mainz, D-55099 Mainz, Germany; fCentro Universitario de Ciencias Exactas e Ingenierías, University of Guadalajara, 44430 Guadalajara, Mexico; and gDr. August Wolff GmbH & Co. KG Arzneimittel, 33611 Bielefeld, Germany Edited by Benjamin F. Cravatt, The Scripps Research Institute, La Jolla, CA, and approved May 10, 2017 (received for review March 14, 2017) The extracellular effects of the endocannabinoids anandamide and ECs over arachidonate and other N-acylethanolamines (NAEs) 2-arachidonoyl glycerol are terminated by enzymatic hydrolysis after (15–19). However, although suitable inhibitors are available for crossing cellular membranes by facilitated diffusion. The lack of potent most targets within the ECS (20), the existing AEA uptake in- and selective inhibitors for endocannabinoid transport has prevented hibitors lack potency and show poor selectivity over the other the molecular characterization of this process, thus hindering its components of the ECS, in particular FAAH (21, 22).
    [Show full text]
  • Functional Selectivity at the Cannabinoid Receptor Both Endogenously and Exogenously Expressed in a Variety of Cell Lines and Tissues
    A Study of Functional Selectivity at the Cannabinoid Type 1 Receptor Richard Priestley, BSc (Hons) Thesis submitted to the University of Nottingham for the degree of Doctor of Philosophy July 2015 1 Abstract The cannabinoid CB1 receptor is a G protein-coupled receptor (GPCR) which is important in the regulation of neuronal function, predominately via coupling to heterotrimeric Gi/o proteins. The receptor has also been shown to interact with a variety of other intracellular signalling mediators, including other G proteins, several members of the mitogen activated kinase (MAP) superfamily and β- arrestins. The CB1 receptor is recognised by an array of structurally distinct endogenous and exogenous ligands and a growing body of evidence indicates that ligands acting at GPCRs are able to differently activate specific signalling pathways, a phenomenon known as functional selectivity or biased agonism. This is important in future drug development as it may be possible to produce drugs which selectively activate signalling pathways linked to therapeutic benefits, while minimising activation of those associated with unwanted side effects. The main aim of this thesis, therefore, was to investigate ligand-selective functional selectivity at the cannabinoid CB1 receptor both endogenously and exogenously expressed in a variety of cell lines. Chinese hamster ovary (CHO) and human embryonic kidney (HEK 293) cells stably transfected with the human recombinant CB1 receptor and untransfected murine Neuro 2a (N2a) cells, were exposed to a number of cannabinoid
    [Show full text]
  • The Serine Hydrolases MAGL, ABHD6 and ABHD12 As Guardians of 2-Arachidonoylglycerol Signalling Through Can- Nabinoid Receptors
    Acta Physiol 2012, 204, 267–276 REVIEW The serine hydrolases MAGL, ABHD6 and ABHD12 as guardians of 2-arachidonoylglycerol signalling through can- nabinoid receptors J. R. Savinainen, S. M. Saario and J. T. Laitinen School of Medicine, Institute of Biomedicine/Physiology, University of Eastern Finland (UEF), Kuopio, Finland Received 25 February 2011, Abstract revision requested 10 March 2011, The endocannabinoid 2-arachidonoylglycerol (2-AG) is a lipid mediator revision received 11 March 2011, involved in various physiological processes. In response to neural activity, accepted 12 March 2011 Correspondence: J. T. Laitinen, 2-AG is synthesized post-synaptically, then activates pre-synaptic cannabinoid PhD, School of Medicine, Institute CB1 receptors (CB1Rs) in a retrograde manner, resulting in transient and long- of Biomedicine/Physiology, lasting reduction of neurotransmitter release. The signalling competence of University of Eastern Finland 2-AG is tightly regulated by the balanced action between ‘on demand’ bio- (UEF), POB 1627, FI-70211 synthesis and degradation. We review recent research on monoacylglycerol Kuopio, Finland. lipase (MAGL), ABHD6 and ABHD12, three serine hydrolases that together E-mail: jarmo.laitinen@uef.fi account for approx. 99% of brain 2-AG hydrolase activity. MAGL is Re-use of this article is permitted responsible for approx. 85% of 2-AG hydrolysis and colocalizes with CB1R in in accordance with the Terms and axon terminals. It is therefore ideally positioned to terminate 2-AG-CB1R Conditions set out at http://wiley signalling regardless of the source of this endocannabinoid. Its acute phar- onlinelibrary.com/onlineopen# macological inhibition leads to 2-AG accumulation and CB1R-mediated OnlineOpen_Terms behavioural responses.
    [Show full text]
  • Cutting Edge: Dysregulated Endocannabinoid-Rheostat For
    Cutting Edge: Dysregulated Endocannabinoid-Rheostat for Plasmacytoid Dendritic Cell Activation in a Systemic Lupus Endophenotype This information is current as of September 23, 2021. Oindrila Rahaman, Roopkatha Bhattacharya, Chinky Shiu Chen Liu, Deblina Raychaudhuri, Amrit Raj Ghosh, Purbita Bandopadhyay, Santu Pal, Rudra Prasad Goswami, Geetabali Sircar, Parasar Ghosh and Dipyaman Ganguly J Immunol published online 6 February 2019 Downloaded from http://www.jimmunol.org/content/early/2019/02/05/jimmun ol.1801521 http://www.jimmunol.org/ Supplementary http://www.jimmunol.org/content/suppl/2019/02/05/jimmunol.180152 Material 1.DCSupplemental Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists by guest on September 23, 2021 • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2019 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Published February 6,
    [Show full text]
  • Targeting the Cannabinoid and Mu Opioid Receptors with Heterodimerized and Allosteric Ligands
    Targeting the cannabinoid and mu opioid receptors with heterodimerized and allosteric ligands Ph.D. Thesis Szabolcs Dvorácskó Supervisor: Dr. Csaba Tömböly Universitiy of Szeged, Faculty of Medicine Doctoral School of Theoretical Medicine Laboratory of Chemical Biology, Institute of Biochemistry Biological Research Center of the Hungarian Academy of Sciences Szeged, Hungary 2019 TABLE OF CONTENTS LIST OF PUBLICATIONS ...................................................................................................... i ABBREVIATIONS ................................................................................................................. iv ACKNOWLEDGEMENTS .................................................................................................... vi 1. Introduction .......................................................................................................................... 1 1.1. The cannabinoid system ...................................................................................................... 1 1.1.1. Cannabinoid receptors ...................................................................................................... 1 1.1.2. Lipid type endocannabinoids ........................................................................................... 2 1.1.3. Hemopressins (Pepcans), the putative peptide endocannabinoids ................................... 2 1.1.4. Phyto- and synthetic cannabinoids ................................................................................... 4 1.2. The opioid
    [Show full text]
  • Since the Discovery of the Cannabinoid Receptors and Their
    Beyond the direct activation of cannabinoid receptors: new strategies to modulate the endocannabinoid system in CNS-related diseases Andrea Chiccaa, Chiara Arenaa,b, Clementina Manerab aInstitute of Biochemistry and Molecular Medicine, National Center of Competence in Research TransCure, University of Bern, CH 3012 Bern, Switzerland; bDepartment of Pharmacy, University of Pisa, via Bonanno 6, 56126 Pisa, Italy *To whom correspondence should be addressed. A.C.: email address: [email protected]; telephone: +41 (0) 31 6314125 Abstract Endocannabinoids (ECs) are signalling lipids which exert their actions by activation cannabinoid receptor type-1 (CB1) and type-2 (CB2). These receptors are involved in many physiological and pathological processes in the central nervous system (CNS) and in the periphery. Despite many potent and selective receptor ligands have been generated over the last two decades, this class of compounds achieved only a very limited therapeutic success, mainly because of the CB1-mediated side effects. The endocannabinoid system (ECS) offers several therapeutic opportunities beyond the direct activation of cannabinoid receptors. The modulation of EC levels in vivo represents an interesting therapeutic perspective for several CNS-related diseases. The main hydrolytic enzymes are fatty acid amide hydrolase (FAAH) for anandamide (AEA) and monoacylglycerol lipase (MAGL) and ,-hydrolase domain-6 (ABHD6) and -12 (ABHD12) for 2-arachidonoyl glycerol (2-AG). EC metabolism is also regulated by COX-2 activity which generates oxygenated-products of AEA and 2-AG, named prostamides and prostaglandin-glycerol esters, respectively. Based on the literature and patent literature this review provides an overview of the different classes of inhibitors for FAAH, MAGL, ABHDs and COX-2 used as tool compounds and for clinical development with a special focus on CNS-related diseases.
    [Show full text]
  • ABHD12 Controls Brain Lysophosphatidylserine Pathways That Are Deregulated in a Murine Model of the Neurodegenerative Disease PHARC
    ABHD12 controls brain lysophosphatidylserine pathways that are deregulated in a murine model of the neurodegenerative disease PHARC Jacqueline L. Blankmana,b, Jonathan Z. Longa,b, Sunia A. Traugerc, Gary Siuzdakc, and Benjamin F. Cravatta,b,1 aThe Skaggs Institute for Chemical Biology and Departments of bChemical Physiology and cMolecular Biology, The Scripps Research Institute, La Jolla, CA 92037 Edited by David W. Russell, University of Texas Southwestern Medical Center, Dallas, TX, and approved November 30, 2012 (received for review October 1, 2012) Advances in human genetics are leading to the discovery of new could contribute to the metabolism of the endogenous canna- disease-causing mutations at a remarkable rate. Many such muta- binoid 2-arachidonoylglycerol (2-AG) in the nervous system. tions, however, occur in genes that encode for proteins of unknown Nonetheless, the physiological metabolites regulated by ABHD12 function, which limits our molecular understanding of, and ability to in vivo, and the molecular and cellular mechanisms by which this enzyme contributes to PHARC, are unknown. Here, we have devise treatments for, human disease. Here, we use untargeted −/− metabolomics combined with a genetic mouse model to determine addressed these important questions by generating ABHD12 α β mice and analyzing these animals for metabolomic and behavioral that the poorly characterized serine hydrolase / -hydrolase do- −/− < main-containing (ABHD)12, mutations in which cause the human phenotypes. Young ABHD12 mice ( 6 mo old) were mostly normal in their behavior; however, as these animals age, they neurodegenerative disorder PHARC (polyneuropathy, hearing loss, develop an array of PHARC-related phenotypes, including de- ataxia, retinosis pigmentosa, and cataract), is a principal lysophos- −/− fective auditory and motor behavior, with concomitant cellular phatidylserine (LPS) lipase in the mammalian brain.
    [Show full text]
  • For Whom the Endocannabinoid Tolls: Modulation of Innate Immune Function and Implications for Psychiatric Disorders
    Provided by the author(s) and NUI Galway in accordance with publisher policies. Please cite the published version when available. Title For whom the endocannabinoid tolls: Modulation of innate immune function and implications for psychiatric disorders Author(s) Henry, Rebecca J.; Kerr, Daniel M.; Finn, David P.; Roche, Michelle Publication Date 2015-03-17 Henry, Rebecca J., Kerr, Daniel M., Finn, David P., & Roche, Michelle. (2016). For whom the endocannabinoid tolls: Publication Modulation of innate immune function and implications for Information psychiatric disorders. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 64, 167-180. doi: https://doi.org/10.1016/j.pnpbp.2015.03.006 Publisher Elsevier Link to publisher's https://doi.org/10.1016/j.pnpbp.2015.03.006 version Item record http://hdl.handle.net/10379/15694 DOI http://dx.doi.org/10.1016/j.pnpbp.2015.03.006 Downloaded 2021-09-25T07:26:23Z Some rights reserved. For more information, please see the item record link above. Accepted for publication in Progress in Neuro-Psychopharmacology & Biological Psychiatry For whom the endocannabinoid tolls: modulation of innate immune function and implications for psychiatric disorders Rebecca J. Henrya,c+, Daniel M. Kerra,b,c+, David P. Finnb,c, Michelle Rochea,c aPhysiology and bPharmacology and Therapeutics, School of Medicine, cGalway Neuroscience Centre and Centre for Pain Research, NCBES, National University of Ireland, Galway, Ireland. +equal contribution Corresponding Author: Dr Michelle Roche, Physiology, School of Medicine,
    [Show full text]
  • Endocannabinoids As Guardians of Metastasis
    Review Endocannabinoids as Guardians of Metastasis Irmgard Tegeder Institute of Clinical Pharmacology, University Hospital Frankfurt, Germany Correspondence: [email protected] Academic Editor: Xiaofeng Jia Received: 16 November 2015 ; Accepted: 01 February 2016 ; Published: 10 February 2016 Abstract: Endocannabinoids including anandamide and 2-arachidonoylglycerol are involved in cancer pathophysiology in several ways, including tumor growth and progression, peritumoral inflammation, nausea and cancer pain. Recently we showed that the endocannabinoid profiles are deranged during cancer to an extent that this manifests in alterations of plasma endocannabinoids in cancer patients, which was mimicked by similar changes in rodent models of local and metastatic cancer. The present topical review summarizes the complexity of endocannabinoid signaling in the context of tumor growth and metastasis. Keywords: endocannabinoids; anandamide; 2-arachidonoylglycerol; orphan G-protein coupled receptor; immune cells; angiogenesis 1. Introduction Endocannabinoids (eCBs) constitute a growing number of lipid signaling molecules, the most popular being anandamide (AEA) and 2-arachidonoylglycerol (2-AG). They are involved in cancer pathophysiology in several ways, including tumor growth and progression [1], immune (in)tolerance, inflammation [2], nausea [3] and cancer pain [4,5]. Our recent work [6] revealed that the endocannabinoid profiles are deranged during cancer, particularly in metastatic cancer, to an extent that this manifests in alterations of plasma endocannabinoids in cancer patients, which was mimicked by similar changes in rodent models of local and metastatic cancer, suggesting that the monitoring of endocannabinoid profiles might be useful for assessing the individual course of the disease and, possibly, that the derangement of the profiles plays a functional role for cancer progression, potentially giving rise to supportive therapeutic interventions.
    [Show full text]